TY - JOUR
T1 - Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer
AU - Takeda, Sho
AU - Shigeyasu, Kunitoshi
AU - Okugawa, Yoshinaga
AU - Yoshida, Kazuhiro
AU - Mori, Yoshiko
AU - Yano, Shuya
AU - Noma, Kazuhiro
AU - Umeda, Yuzo
AU - Kondo, Yoshitaka
AU - Kishimoto, Hiroyuki
AU - Teraishi, Fuminori
AU - Nagasaka, Takeshi
AU - Tazawa, Hiroshi
AU - Kagawa, Shunsuke
AU - Fujiwara, Toshiyoshi
AU - Goel, Ajay
N1 - Funding Information:
The present work was supported by the CA72851 , CA181572 , CA184792 , CA187956 , and CA202797 grants from the National Cancer Institute , National Institute of Health ; RP140784 from the Cancer Prevention Research Institute of Texas ; grants from the Sammons Cancer Center and Baylor Foundation , as well as funds from the Baylor Scott & White Research Institute, Dallas, TX, USA awarded to AG. This work was also supported by a grant from the Uehara Memorial Foundation , Takeda Science Foundation , and JSPS KAKENHI 17K16557 to KS in Japan.
Publisher Copyright:
© 2018
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role in cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) and its clinical significance remains unclear. Herein, we systematically analyzed a large cohort of 627 colorectal cancer (CRC) specimens, and investigated the expression pattern of ADAR1 and its biological significance on the antizyme inhibitor 1 (AZIN1) RNA editing levels. Both ADAR1 expression and AZIN1 RNA editing levels were significantly elevated in CRC tissues vs. normal mucosa, and these findings correlated with the increased expression of mesenchymal markers, Vimentin (ρ = 0.44) and Fibroblast activation protein (ρ = 0.38). Intriguingly, ADAR1 expression was specifically upregulated in both cancer cells and fibroblasts from cancerous lesions. Conditioned medium from cancer cells led to induction of ADAR1 expression and activation of AZIN1 RNA editing in fibroblasts (p < 0.05). Additionally, edited AZIN1 enhanced the invasive potential of fibroblasts. In conclusion, we provide novel evidence that hyper-editing of AZIN1 enhances the invasive potential of CAFs within the TME in colon and is an important predictor of tumor invasiveness in CRC.
AB - Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role in cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) and its clinical significance remains unclear. Herein, we systematically analyzed a large cohort of 627 colorectal cancer (CRC) specimens, and investigated the expression pattern of ADAR1 and its biological significance on the antizyme inhibitor 1 (AZIN1) RNA editing levels. Both ADAR1 expression and AZIN1 RNA editing levels were significantly elevated in CRC tissues vs. normal mucosa, and these findings correlated with the increased expression of mesenchymal markers, Vimentin (ρ = 0.44) and Fibroblast activation protein (ρ = 0.38). Intriguingly, ADAR1 expression was specifically upregulated in both cancer cells and fibroblasts from cancerous lesions. Conditioned medium from cancer cells led to induction of ADAR1 expression and activation of AZIN1 RNA editing in fibroblasts (p < 0.05). Additionally, edited AZIN1 enhanced the invasive potential of fibroblasts. In conclusion, we provide novel evidence that hyper-editing of AZIN1 enhances the invasive potential of CAFs within the TME in colon and is an important predictor of tumor invasiveness in CRC.
KW - ADAR1
KW - AZIN1
KW - Biomarker
KW - Cancer associated fibroblasts
KW - Colorectal cancer
KW - RNA editing
UR - http://www.scopus.com/inward/record.url?scp=85059133645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059133645&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2018.12.009
DO - 10.1016/j.canlet.2018.12.009
M3 - Article
C2 - 30583079
AN - SCOPUS:85059133645
SN - 0304-3835
VL - 444
SP - 127
EP - 135
JO - Cancer Letters
JF - Cancer Letters
ER -